GMABGenmabRunning, no new patients
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 483 (final count)
- Started
- Jan 13, 2021
- Main results expected
- Oct 13, 2025
- Fully finished
- Apr 2028
- Results posted
- Nov 3, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 4 years, 9 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04628494 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC